Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.05 is 134% above its 5-year average of -0.16, near the high end of its 5-year range (-0.35–0.16).
As of the fiscal period ended Tuesday, June 30, 2026. 38.96% below its 12-month average of 0.09.
Reported quarterly debt to equity ratio; no daily interpolation. Q4 FY2026 (2026-06-30): 0.05.
DEBT TO EQUITY RATIO
0.05
DEBT TO EQUITY RATIO AVG TTM
0.09
DEBT TO EQUITY RATIO AVG 3Y
-0.09
DEBT TO EQUITY RATIO AVG 5Y
-0.16
DEBT TO EQUITY RATIO AVG 10Y
-0.33
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-38.96%
CURRENT VS 3Y AVG
+160.60%
CURRENT VS 5Y AVG
+133.70%
CURRENT VS 10Y AVG
+116.39%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 734 covered companies
CURRENT VS SECTOR MEDIAN
-50.77%
vs the sector median at left
Propanc Biopharma, Inc.
Market Cap
$1.16M
Debt to Equity Ratio
0.05
TTM Avg
0.09
3Y Avg
-0.09
5Y Avg
-0.16
Market Cap
$1.10M
Debt to Equity Ratio
0.13
TTM Avg
0.30
3Y Avg
0.57
5Y Avg
0.57
Market Cap
$1.08M
Debt to Equity Ratio
0.14
TTM Avg
0.76
3Y Avg
0.50
5Y Avg
0.30
Market Cap
$1.02M
Debt to Equity Ratio
0.00
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$1.33M
Debt to Equity Ratio
N/A
TTM Avg
0.05
3Y Avg
0.05
5Y Avg
0.05
Market Cap
$1.36M
Debt to Equity Ratio
0.01
TTM Avg
0.02
3Y Avg
0.01
5Y Avg
0.01
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | $1.16M | 0.05 | 0.09 | -0.09 | -0.16 |
| IM Cannabis Corp. (IMCC)vs › | $1.13M | N/A | 2.19 | 1.26 | 0.86 |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.10M | 0.13 | 0.30 | 0.57 | 0.57 |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | 0.14 | 0.76 | 0.50 | 0.30 |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | 0.00 | 0.00 | 0.00 | 0.00 |
| NewcelX Ltd. (NCEL)vs › | $1.32M | 0.06 | 0.03 | 0.02 | 0.01 |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.33M | N/A | 0.05 | 0.05 | 0.05 |
| Genprex, Inc. (GNPX)vs › | $1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.36M | 0.01 | 0.02 | 0.01 | 0.01 |
| INVO Fertility, Inc. (IVF)vs › | $1.44M | 0.24 | 0.63 | 2.77 | 1.75 |
Debt/Equity
0.05
Current Ratio
2.55
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.05 |
| 2026-03-31 | 0.16 |
| 2025-12-31 | 0.06 |
| 2025-09-30 | 0.05 |
| 2025-06-30 | 0.12 |
| 2025-03-31 | 0.07 |
| 2024-12-31 | -0.29 |
| 2024-09-30 | -0.27 |
| 2024-06-30 | -0.25 |
| 2024-03-31 | -0.25 |
| 2023-12-31 | -0.29 |
| 2023-09-30 | -0.17 |
| 2023-06-30 | -0.15 |
| 2023-03-31 | -0.21 |
| 2022-12-31 | -0.25 |
| 2022-09-30 | -0.33 |
| 2022-06-30 | -0.33 |
| 2022-03-31 | -0.35 |
| 2021-12-31 | -0.31 |
| 2021-09-30 | -0.24 |
| 2021-06-30 | -0.19 |
| 2021-03-31 | -0.31 |
| 2020-12-31 | -0.32 |
| 2020-09-30 | -0.30 |
| 2020-06-30 | -0.41 |
| 2020-03-31 | -0.54 |
| 2019-12-31 | -0.49 |
| 2019-09-30 | -0.54 |
| 2019-06-30 | -0.36 |
| 2019-03-31 | -0.58 |
| 2018-12-31 | -0.70 |
| 2018-09-30 | -0.65 |
| 2018-06-30 | -0.67 |
| 2018-03-31 | -0.65 |
| 2017-12-31 | -0.60 |
| 2017-09-30 | -0.69 |
| 2017-06-30 | -0.62 |
| 2017-03-31 | -0.55 |
| 2016-12-31 | -0.47 |
| 2016-09-30 | -0.27 |
| 2016-06-30 | -0.42 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 0.00 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
